A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration

Trial Profile

A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs GB 102 (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ADAGIO
  • Sponsors GrayBug inc.
  • Most Recent Events

    • 19 Sep 2017 According to a GrayBug inc. media release, the company has begun dosing patients in this trial.
    • 24 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 10 Aug 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top